27 - 29 May, 2026
Congress CenterBasel Switzerland Tiffany ThornFounder and CEO at BiVictriX TherapeuticsSpeaker
Profile
Tiffany Thorn is an experienced life sciences executive with over a decade of industry experience in the discovery and development of next-generation Antibody Drug Conjugates (ADCs). As Founder and CEO of BiVictriX Therapeutics, she has been pivotal to spearheading the development strategy for the company’s proprietary Bi-Cygni® approach – an innovate bispecific ADC approach inspired by her earlier career in clinical science.
Agenda Sessions
Conditional Logic-Gated Bispecific ADCs: Harnessing Novel Dual Antigen Fingerprints to Expand Efficacy & Minimise On-Target/Off-Tissue Toxicity
, 14:35View Session